Direct-to-Consumer Marketing Shows How
Results Can Be Achieved Using Minimally Invasive
Technology
CLEARWATER,
Fla., Jan. 3, 2023 /PRNewswire/ --
Apyx® Medical Corporation (NASDAQ: APYX), the
manufacturer of Renuvion®, a proprietary helium plasma
and radiofrequency technology, today announces the launch of its
first-ever direct-to-consumer brand campaign. Entitled
#ThisIsMe, the campaign is aimed at U.S. consumers who
are interested in a minimally invasive procedure with the
Renuvion technology.
The Company's campaign targets consumers with a
variety of creative content that illustrates the personas of
potential patients, all emanating from different walks of life, who
want a younger and tighter-looking appearance of their neck and
chin.
"In an era of superficial innovations, Renuvion
goes beneath the surface to uplift, empower and reshape what's
possible," said Jeff Hoffman,
Vice President of Marketing. "We are a brand that benefits patients
physically with results that benefit them emotionally – creating
confidence they never could have imagined. To connect with our
patients on a personal level,
the #ThisIsMe campaign speaks from their
perspective."
This launch features national digital
advertising, social media and a redesigned website, which is
focused primarily on the consumer and features the creative content
in the brand campaign. These assets are designed to raise awareness
of Renuvion and highlight the benefits of the technology.
The Renuvion brand campaign is launching on
the heels of Renuvion's two recent landmark FDA clearances,
including an important clearance for using the device to improve
the appearance of loose skin on the chin and neck. This
breakthrough "one hour neck procedure" is a single-treatment,
minimally invasive solution that can be performed under a local
anesthetic.
Many in Hollywood have been buzzing about Renuvion
recently. Celebrity plastic surgeon and co-host of the hit
television series Botched Dr. Paul Nassif reported using Renuvion in
a procedure on Passions actress McKenzie Westmore in a recent
People magazine feature. Brazilian
mega-influencer, actress and singer Camila Loures, 27, recently had a procedure
with Renuvion and shared the results with her 18.4 million
Instagram followers. Renuvion was also featured in two episodes of
the December 2022 The Learning
Channel (TLC) series "Awake Surgery", and will be
spotlighted in a February 2023
episode of Lifetime's "The Balancing Act" program.
"With the recent FDA clearances
that Renuvion has received, it's important that Apyx
Medical let potential patients know about its unique capabilities,"
said Todd Hornsby, Executive
Vice President. "Renuvion's safety and efficacy is based on
years of scientific research and clinical evidence which is unique
in this industry."
For a list of physicians, by state, offering
Renuvion in their practice visit
https://RenuvionFinder.com.
For more information visit
Renuvion.com.
About Apyx Medical
Corporation:
Apyx Medical Corporation is an advanced energy
technology company with a passion for elevating people's lives
through innovative products, including its Helium Plasma Technology
products marketed and sold as Renuvion® in the cosmetic
surgery market and J-Plasma® in the hospital surgical
market. Renuvion® and J-Plasma® offer
surgeons a unique ability to provide controlled heat to tissue to
achieve their desired results. The Company also leverages its deep
expertise and decades of experience in unique waveforms through OEM
agreements with other medical device manufacturers. For further
information about the Company and its products, please refer to the
Apyx Medical Corporation website at www.ApyxMedical.com.
Cautionary Statement on
Forward-Looking Statements
Certain matters discussed in this release and
oral statements made from time to time by representatives of the
Company may constitute forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 and
the Federal securities laws. Although the Company believes that the
expectations reflected in such forward-looking statements are based
upon reasonable assumptions, it can give no assurance that its
expectations will be achieved.
All statements other than statements of
historical fact are statements that could be deemed forward-looking
statements, including but not limited to, any statements regarding
the potential impact of the COVID-19 pandemic and the actions by
governments, businesses and individuals in response to the
situation; projections of net revenue, margins, expenses, net
earnings, net earnings per share, or other financial items;
projections or assumptions concerning the possible receipt by the
Company of any regulatory approvals from any government agency or
instrumentality including but not limited to the U.S. Food and Drug
Administration, supply chain disruptions, component shortages,
manufacturing disruptions or logistics challenges; or macroeconomic
or geopolitical matters and the impact of those matters on the
Company's financial performance.
Forward-looking statements and information are
subject to certain risks, trends and uncertainties that could cause
actual results to differ materially from those projected. Many of
these factors are beyond the Company's ability to control or
predict. Important factors that may cause the Company's actual
results to differ materially and that could impact the Company and
the statements contained in this release include but are not
limited to risks, uncertainties and assumptions relating to the
regulatory environment in which the Company is subject to,
including the Company's ability to gain requisite approvals for its
products from the U.S. Food and Drug Administration and other
governmental and regulatory bodies, both domestically and
internationally; the impact of the recent FDA Safety Communication
on our business and operations; factors relating to the effects of
the COVID-19 pandemic; sudden or extreme volatility in commodity
prices and availability, including supply chain disruptions;
changes in general economic, business or demographic conditions or
trends; changes in and effects of the geopolitical environment;
liabilities and costs which the Company may incur from pending or
threatened litigations, claims, disputes or investigations; and
other risks that are described in the Company's Annual Report on
Form 10-K for the fiscal year ended December
31, 2021 and the Company's other filings with the Securities
and Exchange Commission. For forward-looking statements in this
release, the Company claims the protection of the safe harbor for
forward-looking statements contained in the Private Securities
Litigation Reform Act of 1995. The Company assumes no obligation to
update or supplement any forward-looking statements whether as a
result of new information, future events or otherwise.
Media Contact:
Jane Sparango
Coterie Media (for Renuvion)
jane@coteriemedia.com
310-339-1214
Investor Relations Contact:
ICR Westwicke on behalf of Apyx Medical
Corporation
Mike Piccinino, CFA
investor.relations@apyxmedical.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/apyx-medical-corporation-embarks-on-inaugural-brand-campaign-for-renuvion-301712034.html
SOURCE Renuvion